# ImmuPharma PLC Accelerated Bookbuild for the Issue of Equity

- Link: https://www.directorstalkinterviews.com/immupharma-plc-accelerated-bookbuild-issue-equity/412725239
- Published: 2017-03-10T07:09:45+00:00
- Author: Giles Arbor

**ImmuPharma PLC** (LON:IMM), the specialist drug discovery and development company,
has today announced a proposed placing, raising a minimum of £3 million (before 
expenses), via the issue of new ordinary shares of 10p each (“Ordinary Shares”) 
to new and existing investors (the “New Share Placing”).

The New Share Placing will provide ImmuPharma with additional working capital and
will further strengthen the Company’s balance sheet as negotiations continue with
potential partners for Lupuzor™, its lead programme currently in a pivotal Phase
III trial. Additionally, further investment in ImmuPharma’s earlier stage portfolio
and in its P140 peptide platform is also planned.

The New Share Placing is being offered by way of an accelerated bookbuild (“Bookbuild”),
which will be launched immediately following this announcement. It is proposed that
the New Share Placing will be executed at a price of 52p per share (the “Placing
Price”). Northland Capital Partners Limited will be acting as sole bookrunner in
connection with the Bookbuild.

It is expected that the finalisation of the Bookbuild will commence shortly after
the Bookbuild’s launch is announced and a further announcement will be made to confirm
its completion in due course.

Share on: